The interaction between prognostic and pharmacodynamic biomarkers.
Affiliation
Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, UK.Issue Date
2013-10-01
Metadata
Show full item recordAbstract
Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Citation
The interaction between prognostic and pharmacodynamic biomarkers. 2013, 109 (7):1782-5 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2013.527PubMed ID
24002599Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2013.527
Scopus Count
Collections
Related articles
- Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.
- Authors: Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG
- Issue date: 2012 Oct 23
- Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
- Authors: Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C
- Issue date: 2011 Feb 15
- Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
- Authors: Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K
- Issue date: 2008 Nov 15
- Mismatch repair protein MSH2, cytokeratin 18 and cytokeratin 20 expression: clinicopathological correlation and prognostic value in colorectal cancer patients.
- Authors: González JJ, Bernardo CG, Sanz L, Fresno MF, Barbón E, Noval JG, Martínez E
- Issue date: 2007 Dec
- Prognostic biomarkers in colorectal cancer: where do we stand?
- Authors: Sagaert X
- Issue date: 2014 Mar